1.23
+0.1(+8.85%)
Currency In USD
| Previous Close | 1.13 |
| Open | 1.16 |
| Day High | 1.33 |
| Day Low | 1.15 |
| 52-Week High | 2.4 |
| 52-Week Low | 0.85 |
| Volume | 533,594 |
| Average Volume | 173,059 |
| Market Cap | 28.17M |
| PE | -1.52 |
| EPS | -0.81 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.14 |
| Change | 0.1 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $102.5 as of February 05, 2025 at a share price of $1.23. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $418.37 as of February 05, 2025 at a share price of $1.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
GlobeNewswire Inc.
Yesterday at 2:00 PM GMT
Regulatory approval follows FemaSeed U.S. FDA-clearance announced September 2023 and EU CE mark approval announced June 2024ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significa
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
GlobeNewswire Inc.
Jan 30, 2025 1:30 PM GMT
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraceptionATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical i
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
GlobeNewswire Inc.
Jan 16, 2025 1:30 PM GMT
FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addre